Aurora Expands Leading Portfolio of High-Potency Medical Flower Products in Poland

Rhea-AI Summary

Aurora Cannabis (NASDAQ: ACB) launched Black Jelly, a proprietary high-potency medical cannabis cultivar, in Poland on December 11, 2025. Black Jelly offers a cannabinoid profile of THC 27% / CBD <1% and is described as a high-THC sativa derived from Alien Cake 3030 × T037 with sweet black liquorice and fruity terpenes.

The product is grown and manufactured in Aurora's Canadian GACP and EU-GMP certified facilities and joins Farm Gas and Sourdough under the Cannabis flos Aurora portfolio. Aurora said Black Jelly is available to Polish prescribers immediately and emphasized its genetics program, hang-drying and curing techniques, and decade-plus international medical market experience.

Positive

• Launch in Poland on December 11, 2025
• Cannabinoid profile: THC 27% / CBD <1%
• Grown in Canadian GACP and EU-GMP certified facilities
• Adds to Cannabis flos Aurora portfolio alongside Farm Gas and Sourdough

Negative

• None.

News Market Reaction – ACB

+0.44%

36 alerts

+0.44% News Effect

+18.8% Peak in 1 hr 30 min

+$1M Valuation Impact

$258M Market Cap

1.2x Rel. Volume

On the day this news was published, ACB gained 0.44%, reflecting a mild positive market reaction. Argus tracked a peak move of +18.8% during that session. Our momentum scanner triggered 36 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $258M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

THC content: 27% CBD content: <1% Alien Cake 3030 × T037: 2-parent cross +2 more

5 metrics

THC content 27% Black Jelly cannabinoid profile for Polish medical market

CBD content <1% Black Jelly cannabinoid profile for Polish medical market

Alien Cake 3030 × T037 2-parent cross Genetic lineage of Black Jelly cultivar

Experience in global markets More than a decade Aurora’s history in global medical cannabis markets

Share price $4.53 Pre-news price vs 52-week range of $3.4216–$6.9102

Market Reality Check

Price: $3.51 Vol: Volume 1,012,143 is 18% a...

normal vol

$3.51 Last Close

Volume Volume 1,012,143 is 18% above the 20-day average of 855,310 ahead of this news. normal

Technical Price at 4.53 is trading below the 200-day MA at 4.85, signaling a weaker pre-news trend.

Peers on Argus

Ahead of this Poland product launch, ACB was down 1.31% while peers like LFCR, O...

Ahead of this Poland product launch, ACB was down 1.31% while peers like LFCR, OGI, TKNO, SXTC and IRWD showed gains between 2.22% and 3.95%, indicating stock-specific pressure rather than a broad sector move.

Historical Context

5 past events · Latest: Dec 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 08	Leadership appointment	Positive	-2.8%	Named new MD to drive growth in Australia and New Zealand operations.
Dec 02	Distribution partnership	Positive	-1.1%	Signed Leafio partnership to distribute medical brands across Australian pharmacies.
Nov 05	Earnings results	Positive	-1.8%	Reported higher revenue, margins and adjusted EBITDA with solid cash position.
Oct 22	Earnings call notice	Neutral	+1.2%	Announced timing and access details for Q2 2026 results conference call.
Sep 18	Facility investment	Positive	+3.8%	Planned multi-year EU-GMP facility upgrade to boost German flower capacity.

Pattern Detected

Recent positive corporate and financial updates often saw mixed-to-negative next-day price reactions, suggesting a tendency for the stock to trade cautiously around good news.

Recent Company History

Over the last six months, Aurora reported stronger fundamentals, including Q2 fiscal 2026 consolidated net revenue of $90.4M and adjusted EBITDA of $15.4M, alongside a debt-free cannabis business. It also advanced its international footprint via a German EU-GMP facility upgrade and an Australian distribution partnership reaching over 4,000 pharmacies. Leadership changes in Australia and New Zealand further highlighted its global focus. Today’s expansion of a high-potency medical flower portfolio in Poland fits this ongoing strategy of strengthening European medical cannabis markets.

Market Pulse Summary

This announcement highlights Aurora’s strategy of deepening its European medical presence by launchi...

Analysis

This announcement highlights Aurora’s strategy of deepening its European medical presence by launching Black Jelly, a high-THC proprietary cultivar, into Poland. It builds on prior EU-GMP investments and international partnerships aimed at expanding patient access. Investors may track how this product complements existing brands like Farm Gas and Sourdough, prescription uptake in Poland, and future updates on European medical revenue contribution and additional cultivar launches as indicators of traction.

Key Terms

gacp, eu-gmp, cannabinoid, cbd, +2 more

6 terms

gacp medical

"Grown and manufactured in Aurora's Canadian GACP and EU-GMP certified facilities"

Good Agricultural and Collection Practices (GACP) are a set of standards for growing, harvesting, and handling plant materials used in medicines and supplements to make sure they are safe, pure and traceable. For investors, GACP matters because it reduces the risk of contamination, supply disruptions and regulatory rejection—similar to a food-recipes checklist that ensures every batch meets the same quality before it reaches consumers and regulators.

eu-gmp regulatory

"Grown and manufactured in Aurora's Canadian GACP and EU-GMP certified facilities"

EU‑GMP is a regulatory standard that certifies pharmaceutical and related manufacturing facilities in the European Union meet strict quality and safety rules for producing medicines and medical products. For investors, an EU‑GMP certificate is like a trusted food‑safety rating for a factory: it signals lower regulatory and supply risk, access to EU markets, and greater confidence that products are consistently made to required specifications.

cannabinoid medical

"offering a cannabinoid profile of THC 27% / CBD <1%"

Cannabinoids are chemical compounds that interact with the body’s cell signaling system that influences mood, appetite, pain and inflammation; they occur naturally in the cannabis plant, are made by the body, or can be created synthetically. Investors watch cannabinoids because they are the active ingredients that determine a product’s medical effects, consumer demand and regulatory treatment—think of them as the “active ingredient” in a drug or the key flavor that drives sales and legal rules.

cbd medical

"offering a cannabinoid profile of THC 27% / CBD <1%"

Cannabidiol (CBD) is a natural compound found in hemp and cannabis plants that does not produce the “high” associated with THC. Investors care because CBD is sold in a wide range of consumer products and medical treatments, so changes in regulation, clinical evidence, or consumer demand can quickly affect company sales, margins and legal risk — think of it as a product line whose value depends on shifting rules and public trust.

sativa medical

"A high-THC sativa derived from Alien Cake 3030 × T037"

Sativa is a group of cannabis plants and product types commonly associated with energizing, wakeful effects versus the more sedating varieties; it’s often used on labels to signal how a cannabis product might make a user feel. For investors, sativa matters because it helps determine product positioning, consumer demand, regulatory labeling and pricing—think of it like choosing a bold coffee roast that targets a morning crowd rather than an evening decaf.

terpene medical

"and a terpene profile characterized by sweet black liquorice and fruity undertones"

Terpenes are natural aromatic compounds found in many plants and herbs that give them distinctive smells and flavors, similar to how spices give a dish its character. For investors, terpenes matter because they drive product differentiation, influence consumer preference, affect extraction and manufacturing costs, and can shape regulatory and medical claims—factors that impact revenue potential, margins, and supply-chain risk for companies in sectors like cannabis, flavors, fragrances, and wellness.

AI-generated analysis. Not financial advice.

Latest Innovation Brings New Proprietary Cultivar to Polish Patients 

NASDAQ | TSX: ACB

EDMONTON, AB, Dec. 11, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces the launch of Black Jelly, a proprietary cultivar, in Poland, expanding the company's portfolio of high-potency medical cannabis products in one of Europe's fastest-growing markets. Grown and manufactured in Aurora's Canadian GACP and EU-GMP certified facilities, Black Jelly joins Farm Gas and Sourdough under the Cannabis flos Aurora brand portfolio.

"Aurora is uniquely positioned to bring this novel proprietary cultivar to the Polish market thanks to the company's advanced genetic breeding program and unmatched global cultivation excellence," said Andreas Dotterweich, Senior VP of Aurora Europe. "We deeply understand that prescribers want reliable, high-potency medical cannabis options for their patients, and we're proud to offer superior products that consistently meet prescriber and patient needs." 

Black Jelly will be available for Polish prescribers from today, December 11, 2025, offering a cannabinoid profile of THC 27% / CBD <1%. A high-THC sativa derived from Alien Cake 3030 × T037, Black Jelly features dense, large flowers with green and orange hues and a terpene profile characterized by sweet black liquorice and fruity undertones. The cultivar originates from Aurora's world leading genetics program and is crafted using premium hang-drying and curing techniques. 

Aurora continues to strengthen its leadership in international medical cannabis, leveraging its scientific expertise, regulatory knowledge, and commitment to innovation to support patient access and market growth across Europe. With more than a decade of experience in global medical markets, Aurora remains the trusted partner in advancing Poland's medical cannabis ecosystem.

About Aurora Cannabis Inc. 

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Raf, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include Cannabis flos Aurora 27/1, MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands Pedanios, IndiMed and CraftPlant.

Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn. 

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". 

Forward Looking Information  

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the expansion of the Company's portfolio of high-potency medical cannabis products in Poland, the Company's continued leadership in international medical cannabis, competitive advantages in scientific expertise and regulatory knowledge, and continued commitment to innovation to support patient access and market growth across Europe.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-expands-leading-portfolio-of-high-potency-medical-flower-products-in-poland-302638229.html

SOURCE Aurora Cannabis Inc.

FAQ

What is Black Jelly and when did Aurora (ACB) launch it in Poland?

Black Jelly is a proprietary high-potency medical cannabis cultivar launched in Poland on December 11, 2025.

What is the cannabinoid profile of Aurora's Black Jelly (ACB)?

Black Jelly has a reported cannabinoid profile of THC 27% / CBD <1%.

Where is Black Jelly produced for Aurora (ACB) supply to Poland?

Black Jelly is grown and manufactured in Aurora's Canadian GACP and EU-GMP certified facilities.

Which Aurora (ACB) medical flower products will Black Jelly join in Poland?

Black Jelly joins Farm Gas and Sourdough under the Cannabis flos Aurora brand portfolio.

What genetics and sensory profile does Black Jelly (ACB) have?

Black Jelly is a high-THC sativa derived from Alien Cake 3030 × T037 with dense flowers and sweet black liquorice and fruity terpene notes.